On June 22, 2023, Board of Directors of Regulus Therapeutics Inc. appointed Preston S. Klassen, M.D., President and Head of Research & Development, to the Board, to serve until next annual meeting of stockholders and until his successors is duly elected and qualified, or until his earlier death, resignation or removal.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.52 USD | +4.13% | +14.55% | +96.88% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+96.88% | 158M | |
-2.63% | 103B | |
+1.62% | 95.28B | |
+1.46% | 22.15B | |
-16.67% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-13.21% | 16.05B | |
+5.41% | 13.68B | |
+33.57% | 12.17B |
- Stock Market
- Equities
- RGLS Stock
- News Regulus Therapeutics Inc.
- Regulus Therapeutics Inc. Appoints Preston S. Klassen to the Board